An Introduction to Parkinson's Disease
Parkinson’s disease (PD), the most common movement disorder, is characterized by dopamine deficiency and motor symptoms, such as tremor, rigidity, bradykinesia and impaired balance; non-motor symptoms are increasingly being recognized as important too. Despite advances in our understanding of PD by functional genetics, brain imaging and biomarker detection, it remains incurable. While levodopa remains the mainstay of therapy, other treatments include levodopa plus carbidopa (oral/gel infusion), dopamine agonists, MAO-B and COMT inhibitors, anticholinergics and amantadine. Latest approvals include opicapone, a COMT inhibitor, and istradefylline, an adenosine A2A antagonist; both boost the effect of levodopa for better symptom control. Investigational approaches include disease-modifying therapies targeting α-synuclein and its pathways, immunotherapies, stem-cell therapy and non-pharmacological interventions targeting motor symptoms, including gene therapy and adaptive deep-brain stimulation.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Parkinson's Disease Content
Mya C Schiess, MDS 2020 – Stem Cell Therapy for Parkinson’s Disease (Part 1)
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. What is known about the role of inflammation in the […]
Mya C Schiess, MDS 2020 – Stem Cell Therapy for Parkinson’s Disease (Part 2)
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. Could you tell us about the design of your phase […]
Camille Carroll, MDS 2020 – Results of the PD STAT Study
It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590. Questions What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06) […]
Tanya Simuni, MDS 2020 – Update on Clinical Trials in Parkinson’s Disease
We were fortunate to have the opportunity to speak with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) following her session entitled: Update on Recent Clinical Trials – Parkinson’s Disease. Questions 1. Could you give us a brief overview of the role of α-synuclein in the pathogenesis of Parkinson’s disease (PD) and its potential […]
Klaus Seppi & Marina Peball, MDS 2020 – Nabilone for the Non-motor Symptoms of Parkinson’s Disease
Klaus Seppi and Marina Peball (Innsbruck Medical University, Innsbruck, Austria) both kindly joined touchNEUROLOGY to share the promising results from their presentation entitled: Effects of Nabilone on Non-motor Symptoms of Parkinson’s Disease – A Randomised Placebo-controlled Study (The NMS-Nab Study). ClinicalTrials.gov identifier: NCT03769896. Questions 1. Could you give us a brief overview of non-motor symptoms in Parkinson’s […]
Georg Ebersbach, MDS 2020 – Opicapone’s Potential as a First-line Adjunctive Therapy for Motor Fluctuations of Parkinson’s Disease
Georg Ebersbach (Movement Disorders Clinic, Beelitz-Heilstaetten, Beelitz, Germany) kindly took the time to talk us through the findings of his presentation entitled: Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II. ClinicalTrials.gov identifiers for the […]
Heinz Reichmann, MDS 2020 – Gut Microbiome and Parkinson’s Disease
As always, we were pleased to have the opportunity to catch-up with valued editorial board member Heinz Reichmann (Technische Universität Dresden, Dresden, Germany), who spoke to us on the topic of the lecture he gave during the on-demand sessions entitled: The Gut Microbiome in the Pathogenesis of Parkinson’s Disease. Questions 1. Could you tell us […]
WBD 2020: EAN Interview with Prof. Elena Moro and Prof. Günther Deuschl
Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN). On World Brain Day 2020, Professor Günther Deuschl, EAN Past President, gets interviewed by Professor Elena Moro, EAN Secretary General, about research and treatment on Parkinson’s disease.
WBD 2020: EAN Interview with Joke Jaarsma, Joe Condon and Veerle Aertsen
Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN). On this World Brain Day, the European Federation of Neurological Associations (EFNA) president Joke Jaarsma is interviewing two patients with Parkinson’s disease (PD) on their views to improve clinical care in PD. Veerle Aertsen, vice-president of RaDiOrg, the Belgian Rare Diseases Organisation, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!